These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31837211)

  • 1. Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to tocilizumab treatment.
    Sukharomana M; Udomittipong K; Ruangchira-Urai R; Charuvanij S
    Asian Pac J Allergy Immunol; 2022 Jun; 40(2):172-176. PubMed ID: 31837211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
    Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
    J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Juvenile Idiopathic Arthritis and Secondary Macrophage Activation Syndrome in Latvia from 2009 to 2020: A Nationwide Retrospective Study.
    Lukjanoviča K; Šlēziņa I; Dāvidsone Z; Šantere R; Budarina K; Staņēviča V
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109756
    [No Abstract]   [Full Text] [Related]  

  • 4. Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
    Chellapandian D; Milojevic D
    Front Pediatr; 2023; 11():1123104. PubMed ID: 36891226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.
    Nozawa T; Nishimura K; Ohara A; Hara R; Ito S
    Mod Rheumatol; 2019 May; 29(3):558-562. PubMed ID: 27846755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome.
    Wu J; Sun L; Tang X; Zheng Q; Guo L; Xu L; Li Y; Lu M
    Mod Rheumatol; 2022 Oct; 32(6):1114-1121. PubMed ID: 34971386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.
    Ambler WG; Nanda K; Onel KB; Shenoi S
    Ann Med; 2022 Dec; 54(1):1839-1850. PubMed ID: 35786149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
    Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
    Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis.
    Gupta A; Bagri NK; Tripathy SK; Barwad A; Phulware RH; Hari P
    Rheumatol Int; 2020 Jan; 40(1):153-159. PubMed ID: 31273457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic onset juvenile idiopathic arthritis: a single center experience.
    Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
    Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review.
    Chantarogh S; Vilaiyuk S; Tim-Aroon T; Worawichawong S
    BMC Nephrol; 2017 May; 18(1):159. PubMed ID: 28499374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric systemic juvenile idiopathic arthritis-related lung disease: Description of clinical cohort and review of management.
    Swanson C; Khan EK; Cooper A; Ibarra M; Tam-Williams J
    Pediatr Pulmonol; 2024 Mar; 59(3):724-733. PubMed ID: 38155594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of Refractory Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease with Single-Agent Blockade of IL-1β and IL-18.
    Rood JE; Rezk A; Pogoriler J; Finn LS; Burnham JM; Josephson MB; Bar-Or A; Behrens EM; Canna SW
    J Clin Immunol; 2023 Jan; 43(1):101-108. PubMed ID: 36006569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
    Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Pediatr Res; 2020 Dec; 88(6):934-939. PubMed ID: 32184444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of tocilizumab for interstitial lung disease associated with polyarticular juvenile idiopathic arthritis.
    Maruyama Y; Shigemura T; Kobayashi N; Nakazawa Y
    Pediatr Int; 2022 Jan; 64(1):e14737. PubMed ID: 34724279
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.
    Pacharapakornpong T; Vallibhakara SA; Lerkvaleekul B; Vilaiyuk S
    Rheumatol Int; 2017 Feb; 37(2):251-255. PubMed ID: 27798725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients.
    Minoia F; Tibaldi J; Muratore V; Gallizzi R; Bracaglia C; Arduini A; Comak E; Vougiouka O; Trauzeddel R; Filocamo G; Mastrangelo A; Micalizzi C; Kasapcopur O; Unsal E; Kitoh T; Tsitsami E; Kostik M; Schmid JP; Prader S; Laube G; Maritsi D; Jelusic M; Shenoi S; Vastert S; Ardissino G; Cron RQ; Ravelli A;
    J Pediatr; 2021 Aug; 235():196-202. PubMed ID: 33836183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.
    Sönmez HE; Demir S; Bilginer Y; Özen S
    Clin Rheumatol; 2018 Dec; 37(12):3329-3335. PubMed ID: 29663156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy.
    Ulu K; Aliyev E; Kılıç Könte E; Tanatar A; Türkmen Ş; Doğantan Ş; Kızıldağ Z; Kasap Demir B; Gezgin Yıldırım D; Otar Yener G; Öztürk K; Baba Ö; Açarı C; Kılbaş G; Taşkın SN; Haşlak F; Çağlayan Ş; Bağlan E; Dundar HA; Başaran Ö; Barut K; Karadağ ŞG; Coşkuner T; Sönmez HE; Yüksel S; Kalyoncu M; Bakkaloğlu SA; Ünsal E; Paç Kısaarslan A; Bilginer Y; Aktay Ayaz N; Kasapçopur Ö; Özen S; Sözeri B
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI167-SI172. PubMed ID: 38441301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.